These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28862886)

  • 41. Foreword. Nonalcoholic Fatty Liver Disease.
    Day CP; Anstee QM
    Semin Liver Dis; 2015 Aug; 35(3):203-6. PubMed ID: 26378638
    [No Abstract]   [Full Text] [Related]  

  • 42. Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease.
    Hendy OM; Elsabaawy MM; Aref MM; Khalaf FM; Oda AMA; El Shazly HM
    APMIS; 2017 Jul; 125(7):607-613. PubMed ID: 28430371
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nonalcoholic Fatty Liver Disease and Incident Cardiac Events: The Multi-Ethnic Study of Atherosclerosis.
    Zeb I; Li D; Budoff MJ; Katz R; Lloyd-Jones D; Agatston A; Blumenthal RS; Blaha MJ; Blankstein R; Carr J; Nasir K
    J Am Coll Cardiol; 2016 Apr; 67(16):1965-6. PubMed ID: 27102512
    [No Abstract]   [Full Text] [Related]  

  • 44. The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom.
    Gunn NT; Shiffman ML
    Clin Liver Dis; 2018 Feb; 22(1):109-119. PubMed ID: 29128050
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis.
    Kamada Y; Fujii H; Fujii H; Sawai Y; Doi Y; Uozumi N; Mizutani K; Akita M; Sato M; Kida S; Kinoshita N; Maruyama N; Yakushijin T; Miyazaki M; Ezaki H; Hiramatsu N; Yoshida Y; Kiso S; Imai Y; Kawada N; Takehara T; Miyoshi E
    Proteomics Clin Appl; 2013 Oct; 7(9-10):648-56. PubMed ID: 23775887
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasma cathepsin D levels: a novel tool to predict pediatric hepatic inflammation.
    Walenbergh SM; Houben T; Hendrikx T; Jeurissen ML; van Gorp PJ; Vreugdenhil AC; Adriaanse MP; Buurman WA; Hofker MH; Mosca A; Lindsey PJ; Alisi A; Liccardo D; Panera N; Koek GH; Nobili V; Shiri-Sverdlov R
    Am J Gastroenterol; 2015 Mar; 110(3):462-70. PubMed ID: 25732418
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The management of incidental fatty liver found on imaging. What do we need to do?
    Méndez-Sánchez N; Chavez-Tapia NC; Almeda-Valdes P; Uribe M
    Am J Gastroenterol; 2018 Sep; 113(9):1274-1276. PubMed ID: 29549356
    [No Abstract]   [Full Text] [Related]  

  • 49. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
    Satapathy SK; Sanyal AJ
    Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
    Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O
    World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fighting the fatty liver.
    Drew L
    Nature; 2017 Oct; 550(7675):S102-S103. PubMed ID: 29019968
    [No Abstract]   [Full Text] [Related]  

  • 52. [An Overview of NAFLD/NASH in Japan].
    Kim SR; Kim KI
    Yakugaku Zasshi; 2016; 136(4):565-72. PubMed ID: 27040340
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis.
    Yamasaki Y; Nouso K; Miyahara K; Wada N; Dohi C; Morimoto Y; Kinugasa H; Takeuchi Y; Yasunaka T; Kuwaki K; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Iwasaki Y; Amano M; Nishimura S; Yamamoto K
    J Gastroenterol Hepatol; 2015 Mar; 30(3):528-34. PubMed ID: 25168691
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease.
    Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):61-8. PubMed ID: 25822435
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
    Purnomo HD; Mundhofir FE; Kasno ; Sudijanto E; Darmono ; Daldiyono ; Djokomoeljanto R; Faradz SM
    Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Advances in noninvasive methods for diagnosing nonalcoholic fatty liver disease.
    Shen FF; Lu LG
    J Dig Dis; 2016 Sep; 17(9):565-571. PubMed ID: 27429213
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [NASH (non-alcoholic steatohepatitis): fatty liver or fatal liver disease?].
    Roeb E
    Zentralbl Chir; 2014 Apr; 139(2):168-74. PubMed ID: 22441997
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.
    Golabi P; Sayiner M; Fazel Y; Koenig A; Henry L; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):63-71. PubMed ID: 26469309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Non-alcoholic fatty liver disease (NAFLD)].
    Rau M; Weiss J; Geier A
    Dtsch Med Wochenschr; 2015 Jul; 140(14):1051-5. PubMed ID: 26182253
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.